When Medtronic PLC officials looked across the company to determine what they call the firm's "cost of poor execution," they made a shocking discovery: the device giant was spending upwards of $150m to conduct corrective and preventive action (CAPA) activities at its various manufacturing sites.
Under its "cost of poor execution" initiative, Medtronic calculates "the dollars associated with poor-quality things that happen," said Luann Pendy,...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?